Selected Publications
-
article
- Direct-to-Consumer Pharmacies: Disruptive Innovation or More Complexity?. Journal of general internal medicine. 39:2131-2132. 2024
- Tackling the excesses of pharmaceutical marketing and promotion.. BMJ (Clinical research ed.). -. 2024
- Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage.. BMJ (Clinical research ed.). -. 2024
- Randomized Experiments to Reduce Overuse of Health Care: A Scoping Review.. Medical care. 62:263-269. 2024
- Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022.. JAMA dermatology. 160:226-229. 2024
- Medicaid Expansion And Outpatient Cardiovascular Care Use Among Low-Income Nonelderly Adults, 2012-15.. Health affairs (Project Hope). 42:1586-1594. 2023
- Digital Privacy and Data Protection: From Ethical Principles to Action.. The American journal of bioethics : AJOB. 23:24-26. 2023
- Association of High-Deductible Health Plans With Health Care Use and Costs for Patients With Cardiovascular Disease.. Journal of the American Heart Association. 12:-. 2023
- Payer-Negotiated Prices for Cardiac Electrophysiology Procedures at 2022-2023 Top 100 US News & World Report for Cardiology and Heart Surgery Hospitals.. Circulation. Arrhythmia and electrophysiology. 16:-. 2023
- Medical journals and advertiser tracking-Consequences for patients, clinicians, and editors.. Digital health. -. 2023
- Consumer Views on Privacy Protections and Sharing of Personal Digital Health Information.. JAMA network open. 6:-. 2023
- Consumer Confidence in Public and Private Organizations to Use Their Digital Health Data Responsibly.. Journal of general internal medicine. 38:1087-1090. 2022
- Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.. JAMA health forum. 3:-. 2022
- Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.. JAMA health forum. 3:-. 2022
- Prevalence of Third-party Tracking on Medical Journal Websites.. JAMA health forum. 3:-. 2022
- An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher.. American journal of public health. 111:1923-1926. 2021
- Assessing community health research capacity across stakeholders: adapting a tool.. Health promotion international. 36:1198-1208. 2021
- Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal.. The American journal of emergency medicine. 154-157. 2021
- Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics.. Journal of general internal medicine. 35:1928-1930. 2019
- Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.. JAMA network open. 2:-. 2019
- Generic Drugs in the United States: Policies to Address Pricing and Competition.. Clinical pharmacology and therapeutics. 105:329-337. 2019
- The Impact of Off-Patent Drug Acquisitions on Prices.. Journal of general internal medicine. 33:1007-1009. 2018
- Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.. BMJ (Clinical research ed.). -. 2018
- High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.. JAMA. 318:2181-2182. 2017
- The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.. Journal of managed care & specialty pharmacy. 23:1066-1076. 2017
- Prioritization of Generic Drug Review-Reply.. JAMA internal medicine. 177:141-142. 2017
- The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths.. The New England journal of medicine. 375:2213-2215. 2016
- Generic Drug Approvals Since the 1984 Hatch-Waxman Act.. JAMA internal medicine. 176:1391-3. 2016